MAGE-TAB Version 1.1 Comment[MetaboBank accession] MTBKS257 Study Title Effects of treatment of differentiated thyroid cancer with radioactive iodine on the serum metabolome (LC-MS) Study Description Differentiated thyroid cancer patients were treated with tyrogen (recombinant thyroid-stimulating hormone) on day -2 and 1.11 GBq of 131-I on day 0. Serum metabolomes before (day 0) and after (day 30) radioisotope therapy (Radioisotope therapy) was compared to discover biomarkers to evaluate treatment efficacy. Experimental Design compound treatment design Experimental Factor Name Administration of Tylogen and 131-I Experimental Factor Type Administration of Tylogen and 131-I Person Last Name Tatara Person First Name Yota Person Mid Initials Person Affiliation Graduate School of Medicine, Hirosaki University Person Roles submitter PubMed ID Publication DOI Protocol Name Sample collection Extraction Chromatography Mass spectrometry Data processing Metabolite identification Protocol Type Sample collection Extraction Chromatography Mass spectrometry Data processing Metabolite identification Protocol Description Serum samples were collected from patients and stored in a deep freezer. Ten µL urine was pipetted onto a filter containing isotopically-labeled internal standards on a 96-well-plate, dried under a nitrogen stream using a positive pressure manifold (Biotage AB), and 50 µL of 5% phenyl isothiocyanate (PITC) solution were added to each well to derivatize amino acids and biogenic amines. After 1h incubation time at room temperature, the plate was dried again. To extract the metabolites, 300 µL of 5 mM ammonium acetate in methanol were pipetted to each filter and incubated for 30 min. The extract was eluted into a new 96-well-plate using the positive pressure manifold. For further LC-MS/MS analyses 150 µL of the extract was diluted with an equal volume of water. The LC-MS/MS system was comprised of a HPLC system coupled to a mass spectrometer in electrospray ionization mode. Amino acids and biogenic amines were analyzed via LC-MS/MS in positive mode. Ten microliters of the sample extract were injected onto a HPLC C18 column at 40°C using a 10 min solvent gradient employing 0.2% formic acid in water (solvent A) and 0.2% formic acid in acetonitrile (solvent B). Quadrupole mass spectrometer settings for LC-MS/MS mode are as follows: curtain gas, 45; ion spray voltage, 5500 V; temperature, 500°C; ion source gas 1, 60 psi; ion source gas 2, 70 psi; CAD gas, 6 psi; entrance potential, 10 V; collision cell exit potential, 15 V. Data acquisition: Analyst 1.6.3 (SCIEX) was used for data acquisition and processing. All metabolites were identified and quantified with isotopically-labeled internal standards and multiple reaction monitoring (MRM) as optimized and provided by Biocrates Inc. Protocol Parameters Post extraction;Derivatization Chromatography instrument;Autosampler model;Column model;Column type;Resolution;Temperature;Guard column Scan polarity;Scan m/z range;Instrument;Ion source;Mass analyzer Protocol Hardware ExionLC AD (AB SCIEX) QTRAP6500+ (AB Sciex) Protocol Software Analyst 1.6.3 (SCIEX) MetIDQ carbon (Biocrates) Public Release Date 2025-06-25 Term Source Name Term Source File Term Source Version SDRF File MTBKS257.sdrf.txt Comment[Study type] targeted metabolite profiling Comment[Experiment type] liquid chromatography-mass spectrometry Comment[Submission type] LC-MS Comment[BioProject] PRJDB20264 Comment[Related study] Comment[Contributor] Satoru Monzen (Department of Radiation Science, Graduate School of Health Sciences, Hirosaki University) Comment[Submission Date] 2025-02-10 Comment[Last Update Date] 2025-06-25